The HOMER1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphoblastoid cell line. This product comprises a heterogeneous pool of Jurkat cells harboring targeted disruptions in the HOMER1 gene, generated using a CRISPR/Cas9-mediated gene disruption strategy. The polyclonal nature of this knockout model captures a spectrum of editing events, enabling robust loss-of-function studies without clonal selection bias.
The Jurkat cell line, originally isolated from a 14-year-old male with acute T cell leukemia, serves as an immortalized human T lymphocyte model widely employed for investigating T cell receptor (TCR) signaling, activation mechanisms, and leukemogenesis. These cells retain key signaling machinery, including TCR/CD3 complexes, CD28 costimulatory receptors, and downstream intracellular cascades, making them an ideal host for studying immunoregulatory proteins such as HOMER1.
HOMER1 encodes a scaffold protein that bridges group I metabotropic glutamate receptors (GRM1 and GRM5) to intracellular effectors, most notably IP3 receptors (IP3Rs) and TRPC channels, facilitating glutamate-induced calcium release from endoplasmic reticulum stores. In Jurkat T cells, HOMER1 additionally integrates into TCR-proximal signaling networks, interacting with SHANK family proteins and calcineurin to modulate calcium-dependent NFAT transcription factor activity. HOMER1 functions downstream of TCR engagement and CD28 costimulation, and upstream of ERK, CREB, and mTORC1 pathways, thereby linking glutamatergic and immune signaling axes.
Disruption of HOMER1 in the Jurkat background abrogates its scaffolding function, leading to altered TCR-induced calcium flux and impaired NFAT-dependent transcriptional programs. This knockout model is particularly relevant for dissecting the molecular convergence of glutamatergic and immune signaling, and for exploring HOMER1??s role in disorders such as schizophrenia, autism spectrum disorder, and immune dysregulation. Moreover, its derivation from a T?cell leukemia cell line renders it valuable for examining the intersection between HOMER1-mediated signaling and leukemia cell proliferation or survival.
Researchers can employ these HOMER1 knockout Jurkat polyclonal cells for a broad range of applications, including calcium signaling analysis via Fluo?4 flow cytometry, NFAT activity monitoring through luciferase reporter assays, and quantitative assessment of NFAT target genes (e.g., IL-2) by RT?qPCR. The model is also suited for co-immunoprecipitation studies to validate HOMER1?CmGluR interactions, Western blotting for phospho?ERK and total HOMER1 levels, and immunofluorescence localization assays. Additionally, these cells provide a genetically defined platform for drug screening targeting neuropsychiatric and immune disorders, as well as for gene editing target validation experiments. For further details on product specifications, validation data, or technical support, please contact Ascent Research.
